Everyone is talking about longevity. Twenty years ago this was a niche field, the preserve of calorie-restriction enthusiasts, rapamycin tinkerers, and a handful of academics counting telomeres. But now it’s everywhere. Altos Labs raised $3 billion before publishing a paper. Tech executive Bryan Johnson livestreamed his blood swaps. Calico, an Alphabet life sciences startup, has been quietly burning through Google money for a decade. And that’s …